CBST – 2011 Q4 Quarterly Report Follow-up; Catalysts Through 2012 and Beyond

CBST: 2011 Q4 Quarterly Report Follow-up; Catalysts Through 2012 and Beyond Thursday, January 19 Cubist announced fourth quarter and full-year 2011 results today that surpassed analyst expectations. Excluding one-time costs, quarterly earnings jumped to 66 cents/share from 24 cents the previous year. This was well above consensus estimates of 31 cents. Profit decreased to 11 […]

LXRX – Lexicon Pharmaceuticals is Overvalued

Lexicon Pharma stocks its drug candidate pipeline with a discovery platform based on mouse gene knockout technology, which has allowed them to study the roles of different proteins in disease and select drug targets accordingly. The company’s major clinical programs are headlined by their candidate for type 2 diabetes, LX4211. LXRX has consistently talked about […]

Preview of ASCO 2012 GU Symposium

The 2012 ASCO Genitourinary Cancers Symposium from February 2-4, 2012. The conference is broken down into 3 days focusing on three main areas: Thursday appears dedicated to prostate cancer, Friday is mostly related to urothelial cancers(penile, urethral, urothelial, and testicular), and Saturday is dedicated to kidney cancer. Abstracts will be released on Tuesday, January 31, […]

CBST – Initiating Coverage

CBST: Initiating Coverage Overview: Cubist is a small commercial stage biotech focused on the development of acute care products. Its revenues are almost entirely derived from the antibiotic Cubicin, used for skin and skin-structure infections. The drug has been one of the most successful recent antibiotic launches, allowing Cubist to focus on building up its […]

ACHN & ARIA – Time To Take Some Profits

Both Achillion and Ariad hit 52-week highs today after running up on positive news. While we continue to believe the companies will be successful, we also believe the stocks are getting fairly expensive and think it is a good time to take profits. Since recommending ARIA on November 10th at $10.72, it has gained 31.25% […]

VVUS – Quick Update – Vivus alters NDA for Qnexa, changes REMS

Vivus Pharmaceuticals (NASDAQ:VVUS)  reached an agreement today with the FDA, to alter both it’s REMS and Label for obesity drug candidate, Qnexa. Previous Proposed Label Management took a very conservative approach when filing the initial NDA.  Given questions about teratogencity of topiramate, one of the active ingredients in Qnexa, Vivus’s management proposed a label that […]

ACHN & INHX: Two HCV Drugmakers In The Spotlight

ACHN v. INHX: Two HCV Drugmakers In The Spotlight Achillion: On Wednesday January 4, Achillion announced it had received Fast-Track designation from the FDA for its experimental HCV drug ACH-1625. A positive development for sure- investors reacted by lifting the stock 1% on a mostly down day for biotechs. Fast Track status is reserved for […]

AVEO – Quick take on top-line data

AVEO Pharmaceuticals(NASDAQ: AVEO) kicked off the 2012 trading year with news from their Phase 3 trial, TIVO-1. AVEO announced that Tivozanib had demonstrated superiority over sorafenib in the primary endpoint of progression-free survival (PFS) in TIVO-1, a global, randomized Phase 3 clinical trial evaluating the efficacy and safety of Tivozanib compared to Nexavar(sorafenib) in patients […]

AIS – “Lies, Damn Lies, and Statistics”

Anatres Pharma (AIS) has been the subject of biotech stock buzz lately, due to two closely spaced news events concerning the company’s proprietary topical gel products. The failure of LibiGel, a testosterone product for female sexual dysfunction, in phase 3 efficacy trials conducted by their partner BioSante Pharma (BPAX), has grabbed the headlines. While that […]

MITI – Initiate Coverage

Micromet: Initiate Coverage Background: Micromet specializes in the development of cancer drugs based on a new class of therapeutics called “bispecific antibodies.” These novel antibodies are capable of recognizing and binding two different antigens and have been termed “bispecific T-cell engagers” or BiTE antibodies. Bispecific antibodies are part of a new generation of more advanced […]